FindTrial
Sign In

Very Short-Term Effects of Evolocumab in Patients Undergoing Percutaneous Coronary Angioplasty (PCI)

Clinical Study of Biomarker Variability with Evolocumab in Patients Undergoing Percutaneous Coronary Angioplasty (PCI) - Very Short-Term Effects of Evolocumab for Coronary Artery Disease

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000053575
Enrollment
50
Registered
2024-02-08
Start date
2021-06-28
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic Heart Disease

Interventions

Administared single dose of Evolocumab 420mg

Sponsors

University of Fukui
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: coronary artery disease patients with significant stenotic lesions who performed NIRS-IVUS at the target lesions at the time of coronary angiography for diagnosis

Exclusion criteria

Exclusion criteria: We excluded patients with acute coronary syndrome, chronic total occlusion, patients who could not be followed with NIRS-IVUS

Design outcomes

Primary

MeasureTime frame
Evaluation of biomarkier variability—

Countries

Japan

Contacts

Public ContactHiroyasu Uzui

University of Fukui Department of Cardiovascular Medicine

huzui@u-fukui.ac.jp+81-776-61-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026